SEC Form 4 · accession 0001209191-16-088713
Alaunos Therapeutics, Inc. · TCRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Anthony Cannon
Director
Period of report
Dec 31, 2015
Accepted (ET)
Jan 5, 2016 · 4:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001107421
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Dec 31, 2015 | F | 1,462 | $8.31 | D | 304,479 | D | |
| Common StockF1 | Dec 31, 2015 | F | 4,177 | $8.31 | D | 300,302 | D | |
| Common StockF3 | Dec 31, 2015 | A | 26,661 | $0.00 | A | 326,963 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants.
- F2Includes 4,817 shares acquired in a pro rata distribution by Intrexon Corporation.
- F326,661 shares vest on 12/31/2016.